Competition may heat up soon in the developing ultrasound bone densitometry market. Bone densitometry vendor Norland has acquired rights to distribute worldwide all existing and future ultrasound bone measurement systems developed by Canadian vendor
Competition may heat up soon in the developing ultrasound bone densitometry market. Bone densitometry vendor Norland has acquired rights to distribute worldwide all existing and future ultrasound bone measurement systems developed by Canadian vendor IMRO.
The device developed by IMRO provides ultrasound bone measurement at the heel and will be sold by Norland as Paris. The bone department of McGill University in Toronto has selected the IMRO device to be used exclusively in an ongoing clinical study, according to White Plains, NY-based Norland.
Norland expects to begin marketing Paris shortly in Europe, Latin America, and the Pacific Rim, and an application for Food and Drug Administration 510(k) clearance should be filed by the end of the year, according to the company.
In other Norland news, shareholders have approved its acquisition of Norland Corp., the Ft. Atkinson, WI-based company that manufactures the DEXA (dual-energy x-ray absorptiometry) scanners that Norland distributes (SCAN 3/19/97).
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Month, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.